{"title":"Role of non-animal 3D models in H. pylori associated gastric carcinogenesis: Insights and future perspectives","authors":"Randhir Singh, Dyumn Dwivedi, Anshu Yadav, Maya Chaturvedi, Sourabh Tyagi, Hemant Ritturaj Kushwaha, Rupesh Chaturvedi, Shruti Mishra","doi":"10.1016/j.ctarc.2026.101363","DOIUrl":null,"url":null,"abstract":"<div><div>Three-dimensional (3D) gastric organoids have become valuable experimental models for gastric cancer research, as they closely mirror tumour architecture, molecular features, and treatment responses. Unlike two-dimensional cultures and animal models, gastric organoids capture key physiological and pathological characteristics of the human stomach, allowing more meaningful investigation of tumour development, host–microbe interactions, and epithelial–stromal crosstalk. These systems retain the genetic and phenotypic traits of their tissue of origin, making them suitable for both mechanistic studies and long-term experimentation.</div><div>This review outlines the development of gastric organoid technology, from early advances in adult stem cell–derived cultures to recent methodological refinements that have expanded their experimental and clinical relevance. We discuss how organoid models have helped address the challenge posed by the marked molecular and histological heterogeneity of gastric cancer, which continues to complicate diagnosis and therapeutics. In this regard, patient-derived gastric organoids and associated biobanks have shown strong potential as predictive tools for drug response, as they reliably preserve tumour structure and gene expression patterns observed in primary tissues. In addition, we highlight recent improvements in culture matrices and experimental approaches that have enhanced organoid robustness and reproducibility. The growing use of gastric organoids as preclinical platforms for drug screening and the study of cancer-related signaling pathways reflects the rapid maturation of the field. We consider current limitations, technical challenges, and future directions for gastric organoid research, emphasizing their role as complementary models that bridge the gap between conventional in vitro systems and in vivo studies in gastric cancer.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101363"},"PeriodicalIF":3.5000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294226002741","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/15 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Three-dimensional (3D) gastric organoids have become valuable experimental models for gastric cancer research, as they closely mirror tumour architecture, molecular features, and treatment responses. Unlike two-dimensional cultures and animal models, gastric organoids capture key physiological and pathological characteristics of the human stomach, allowing more meaningful investigation of tumour development, host–microbe interactions, and epithelial–stromal crosstalk. These systems retain the genetic and phenotypic traits of their tissue of origin, making them suitable for both mechanistic studies and long-term experimentation.
This review outlines the development of gastric organoid technology, from early advances in adult stem cell–derived cultures to recent methodological refinements that have expanded their experimental and clinical relevance. We discuss how organoid models have helped address the challenge posed by the marked molecular and histological heterogeneity of gastric cancer, which continues to complicate diagnosis and therapeutics. In this regard, patient-derived gastric organoids and associated biobanks have shown strong potential as predictive tools for drug response, as they reliably preserve tumour structure and gene expression patterns observed in primary tissues. In addition, we highlight recent improvements in culture matrices and experimental approaches that have enhanced organoid robustness and reproducibility. The growing use of gastric organoids as preclinical platforms for drug screening and the study of cancer-related signaling pathways reflects the rapid maturation of the field. We consider current limitations, technical challenges, and future directions for gastric organoid research, emphasizing their role as complementary models that bridge the gap between conventional in vitro systems and in vivo studies in gastric cancer.
期刊介绍:
Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.